Clinical Profile of Patients with Post-COVID-19 Mucormycosis at a Tertiary Care Center
Background: Mucormycosis is a serious but rare fungal infection, but there was an increase in incidence in the COVID-19 phase. The study aims to throw light on the possible reasons and possible treatment options for optimal outcomes. Objectives: The study aims to formulate the clinical profile of pa...
Saved in:
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wolters Kluwer Medknow Publications
2025-07-01
|
| Series: | Journal of Advanced Lung Health |
| Subjects: | |
| Online Access: | https://journals.lww.com/10.4103/jalh.jalh_65_24 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849425496766414848 |
|---|---|
| author | S. Anju K. A. Ameer P. Arjun Sujith Varghese Abraham |
| author_facet | S. Anju K. A. Ameer P. Arjun Sujith Varghese Abraham |
| author_sort | S. Anju |
| collection | DOAJ |
| description | Background:
Mucormycosis is a serious but rare fungal infection, but there was an increase in incidence in the COVID-19 phase. The study aims to throw light on the possible reasons and possible treatment options for optimal outcomes.
Objectives:
The study aims to formulate the clinical profile of patients admitted with post-COVID-19 mucormycosis at a tertiary care center in South India.
Materials and Methods:
The study population included patients fulfilling the criteria for post-COVID-19 mucormycosis by histopathology examination at KIMS Health, Thiruvananthapuram, Kerala. Using data from electronic medical records, a retrospective cross-sectional study was conducted among 19 participants admitted with post-COVID-19 mucormycosis from January 2021 to December 2021. A clinical profile was identified for each patient based on age, gender, comorbidities, and risk factors. Investigations, including histopathology examination and clinical findings, were also recorded.
Results:
The average age of patients admitted with post-COVID-19 mucormycosis was 59 years. An important observation in the study is that all the patients had rhino-orbital involvement and were diabetic. All of them received antifungal therapy with wound debridement. Intra-cranial extension was found in all cases of mortality in this study. The most used antifungal for post-COVID-19 mucormycosis was Liposomal amphotericin B, followed by oral isavuconazole. Eighty-nine percent of the patients received glucocorticoids during COVID-19 infection.
Interpretation:
The prevalence of diabetes was 83% among patients in another study, whereas our study reported a 100% prevalence of diabetes among patients with post-COVID-19 mucormycosis. A mortality of 26% was reported in the present study.
Conclusion:
Diabetes and cerebral involvement were associated with high mortality in post-COVID-19 mucormycosis, and rhino orbital involvement was the most common form of mucormycosis in post-COVID-19 patients. |
| format | Article |
| id | doaj-art-eba2668e04f94dc1915aee8a4651e4c8 |
| institution | Kabale University |
| issn | 2772-7165 2772-7173 |
| language | English |
| publishDate | 2025-07-01 |
| publisher | Wolters Kluwer Medknow Publications |
| record_format | Article |
| series | Journal of Advanced Lung Health |
| spelling | doaj-art-eba2668e04f94dc1915aee8a4651e4c82025-08-20T03:29:44ZengWolters Kluwer Medknow PublicationsJournal of Advanced Lung Health2772-71652772-71732025-07-015312112310.4103/jalh.jalh_65_24Clinical Profile of Patients with Post-COVID-19 Mucormycosis at a Tertiary Care CenterS. AnjuK. A. AmeerP. ArjunSujith Varghese AbrahamBackground: Mucormycosis is a serious but rare fungal infection, but there was an increase in incidence in the COVID-19 phase. The study aims to throw light on the possible reasons and possible treatment options for optimal outcomes. Objectives: The study aims to formulate the clinical profile of patients admitted with post-COVID-19 mucormycosis at a tertiary care center in South India. Materials and Methods: The study population included patients fulfilling the criteria for post-COVID-19 mucormycosis by histopathology examination at KIMS Health, Thiruvananthapuram, Kerala. Using data from electronic medical records, a retrospective cross-sectional study was conducted among 19 participants admitted with post-COVID-19 mucormycosis from January 2021 to December 2021. A clinical profile was identified for each patient based on age, gender, comorbidities, and risk factors. Investigations, including histopathology examination and clinical findings, were also recorded. Results: The average age of patients admitted with post-COVID-19 mucormycosis was 59 years. An important observation in the study is that all the patients had rhino-orbital involvement and were diabetic. All of them received antifungal therapy with wound debridement. Intra-cranial extension was found in all cases of mortality in this study. The most used antifungal for post-COVID-19 mucormycosis was Liposomal amphotericin B, followed by oral isavuconazole. Eighty-nine percent of the patients received glucocorticoids during COVID-19 infection. Interpretation: The prevalence of diabetes was 83% among patients in another study, whereas our study reported a 100% prevalence of diabetes among patients with post-COVID-19 mucormycosis. A mortality of 26% was reported in the present study. Conclusion: Diabetes and cerebral involvement were associated with high mortality in post-COVID-19 mucormycosis, and rhino orbital involvement was the most common form of mucormycosis in post-COVID-19 patients.https://journals.lww.com/10.4103/jalh.jalh_65_24covid-19indiamucormycosispost-covid-19rhino-orbito cerebral mucormycosis |
| spellingShingle | S. Anju K. A. Ameer P. Arjun Sujith Varghese Abraham Clinical Profile of Patients with Post-COVID-19 Mucormycosis at a Tertiary Care Center Journal of Advanced Lung Health covid-19 india mucormycosis post-covid-19 rhino-orbito cerebral mucormycosis |
| title | Clinical Profile of Patients with Post-COVID-19 Mucormycosis at a Tertiary Care Center |
| title_full | Clinical Profile of Patients with Post-COVID-19 Mucormycosis at a Tertiary Care Center |
| title_fullStr | Clinical Profile of Patients with Post-COVID-19 Mucormycosis at a Tertiary Care Center |
| title_full_unstemmed | Clinical Profile of Patients with Post-COVID-19 Mucormycosis at a Tertiary Care Center |
| title_short | Clinical Profile of Patients with Post-COVID-19 Mucormycosis at a Tertiary Care Center |
| title_sort | clinical profile of patients with post covid 19 mucormycosis at a tertiary care center |
| topic | covid-19 india mucormycosis post-covid-19 rhino-orbito cerebral mucormycosis |
| url | https://journals.lww.com/10.4103/jalh.jalh_65_24 |
| work_keys_str_mv | AT sanju clinicalprofileofpatientswithpostcovid19mucormycosisatatertiarycarecenter AT kaameer clinicalprofileofpatientswithpostcovid19mucormycosisatatertiarycarecenter AT parjun clinicalprofileofpatientswithpostcovid19mucormycosisatatertiarycarecenter AT sujithvargheseabraham clinicalprofileofpatientswithpostcovid19mucormycosisatatertiarycarecenter |